Aims The Korean Association for the Study of the Liver (KASL) Practice Guidelines for
Management of Hepatitis C were first established in 2004, and revised in 2013, when direct …

This review will provide an in-depth discussion on the previous development of nanoparticle-
based drug delivery systems (DDS) and discuss original research data that includes the …

Background The hepatitis C virus (HCV) is a major public health problem and a leading
cause of chronic liver disease. 5 An estimated 180 million people are infected worldwide. 6 …

BACKGROUND & AIMS: Treatment with peginterferon alfa and ribavirin produces a
sustained virologic response (SVR) in approximately 60% of hepatitis C virus (HCV)-infected …

Background: Many patients with chronic hepatitis C have not responded to therapy with
pegylated interferon plus ribavirin. Objective: To evaluate use of peginterferon-α2a plus …

Since the last consensus conference on the management of chronic viral hepatitis, a number
of studies looking at modifications of the standard course of treatment have been published …

Background Efficacy of available therapies for patients with HCV who have previously failed
treatment is limited. Two Phase III, open-label trials in Japan investigated efficacy and safety …

Chronic hepatitis C virus (HCV) infection affects approximately 1.3% of the general US
population and 5–10% of veterans who use Department of Veterans Affairs medical …

Results There are major steps that should be taken to eradicate HCV, including (1) the
development of screening strategies, particularly for groups such as intravenous drug users …

A brief history of the treatment of viral hepatitis C<link href='#fn1'></link> Page 1 REVIEW A
Brief History of the Treatment of Viral Hepatitis C Doris B. Strader, MD* and Leonard B. Seeff …